Panel Supports Sapien But Urges Cautious Rollout
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences’ Sapien transcatheter aortic valve met widespread expectations last week by gaining support for FDA approval from an agency advisory panel, but the experts urged FDA and Edwards to proceed cautiously.